All In Biotech

Drug Trial Radar · NCT05738486

A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)

Investigating the Effect of Different Donanemab Dosing Regimens on ARIA-E and Amyloid Lowering in Adults With Early Symptomatic Alzheimer's Disease

Last checked: Nov 20, 2026Latest source record: Jun 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,175 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,175

Actual

Start

Feb 28, 2023

Primary completion

May 16, 2024

Study completion May 2027

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Feb 22, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 60 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will investigate different donanemab dosing regimens and their effect on the frequency and severity of ARIA-E in adults with early symptomatic Alzheimer's disease (AD) and explore participant characteristics that might predict risk of ARIA. Approximately 375 additional participants will be enrolled in addendum 2. Addendum 3 includes a subset of participants from the main study to receive a single dose. The study will last approximately 91 weeks and include up to 26 visits in the main study.

Conditions

  • Alzheimer's Disease
  • Dementia
  • Brain Diseases
  • Central Nervous System Diseases
  • Nervous System Diseases
  • Neurodegenerative Diseases
  • Neurocognitive Disorders
  • Mental Disorders

Interventions

  • DonanemabDrug

    Administered IV

  • PlaceboDrug

    Administered IV

  • DexamethasoneDrug

    Administered IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Any Occurrence of Amyloid-Related Imaging Abnormality-Edema/Effusion (ARIA-E)Time frame: 24 Weeks

Locations

49 sites in 2 countries. Site status is shown where the registry gives one.

  • MD First Research - Chandler

    Chandler, Arizona

  • Irvine Clinical Research

    Irvine, California

  • Healthy Brain Clinic

    Long Beach, California

  • California Neuroscience Research Medical Group, Inc.

    Sherman Oaks, California

  • JEM Research Institute

    Atlantis, Florida

  • VIN-Julie Schwartzbard

    Aventura, Florida

  • Excel Medical Clinical Trials

    Boca Raton, Florida

  • K2 Medical Research

    Clermont, Florida

  • Brain Matters Research

    Delray Beach, Florida

  • Neuropsychiatric Research Center of Southwest Florida

    Fort Myers, Florida

  • Finlay Medical Research

    Greenacres City, Florida

  • Infinity Clinical Research, LLC

    Hollywood, Florida

  • Jacksonville Center for Clinical Research

    Jacksonville, Florida

  • ClinCloud - Maitland

    Maitland, Florida

  • K2 Medical Research

    Maitland, Florida

  • ClinCloud - Viera

    Melbourne, Florida

  • Suncoast Clinical Research, Inc.

    New Port Richey, Florida

  • Renstar Medical Research

    Ocala, Florida

  • Charter Research - Winter Park

    Orlando, Florida

  • Progressive Medical Research

    Port Orange, Florida

  • Alzheimer's Research and Treatment Center

    Stuart, Florida

  • K2 Medical Research - Tampa

    Tampa, Florida

  • K2 Summit Research

    The Villages, Florida

  • Charter Research - Lady Lake

    The Villages, Florida

  • Alzheimer's Research and Treatment Center

    Wellington, Florida

  • Palm Beach Neurology

    West Palm Beach, Florida

  • Conquest Research

    Winter Park, Florida

  • Columbus Memory Center, LLC

    Columbus, Georgia

  • CenExel iResearch, LLC

    Decatur, Georgia

  • Center for Advanced Research & Education

    Gainesville, Georgia

  • CenExel iResearch, LLC

    Savannah, Georgia

  • MedVadis Research Corporation

    Waltham, Massachusetts

  • Adams Clinical

    Watertown, Massachusetts

  • QUEST Research Institute

    Farmington Hills, Michigan

  • The Cognitive and Research Center of New Jersey

    Springfield, New Jersey

  • Butler Hospital

    Providence, Rhode Island

  • Neurology Clinic, P.C.

    Cordova, Tennessee

  • Gadolin Research

    Beaumont, Texas

  • Kerwin Medical Center

    Dallas, Texas

  • The University of Texas Health Science Center at Houston

    Houston, Texas

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.